MMP1
Interstitial collagenase
As of the edition of 20 October 2026, MMP1 (interstitial collagenase, UniProt P03956) has 3 drugs tested at it and 9 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P03956
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 15
- Disease areas
- Infections; Skin and connective tissue; Lungs and airways; Urinary and reproductive; Cancer; Heart and blood vessels; Immune system; Inherited and neonatal
- Registered trials of its drugs
- 237
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Doxycycline anhydrous | Marketed | Phase 4 | none listed |
| Rebimastat | Stopped | Phase 3 | none listed |
| Marimastat | Active | Phase 3 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Engaged | 7 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| Bristol Myers Squibb | Route A |
The other 7 companies at MMP1
In the product9 companies in all; 7 are not named here, and no score is.
See the 9 companies at MMP1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.